Last updated: September 1, 2026
Romiplostim, marketed by Amgen as Nplate, is an established thrombopoietin receptor agonist used primarily for immune thrombocytopenia (ITP) and, in the United States, severe aplastic anemia (SAA) after inadequate response to immunosuppressive therapy. Its commercial profile is resilient because it treats chronic hematology patients, has no FDA-approved biosimilar competition, and retains clinical utility in patients who fail or cannot tolerate oral alternatives.
Nplate revenue has generally remained near or above $1 billion annually, making romiplostim a material Amgen product but not a core driver of the company’s total revenue. The principal long-term risks are oral TPO receptor agonist competition, payer pressure, treatment migration, and eventual biologic competition rather than a near-term loss of regulatory exclusivity.
What is romiplostim and how does Nplate work?
Romiplostim is a recombinant peptibody that activates the thrombopoietin receptor, also known as c-Mpl. It stimulates megakaryocyte proliferation and platelet production.
Nplate is administered by subcutaneous injection, generally once weekly. Dosing is adjusted according to platelet counts, with the objective of reducing bleeding risk rather than normalizing platelet counts. Excessive platelet production creates risks that require regular monitoring, including thrombosis and excessive thrombocytosis.
| Attribute |
Romiplostim |
| Brand |
Nplate |
| Active molecule |
Romiplostim |
| Developer and global originator |
Amgen |
| Drug class |
Thrombopoietin receptor agonist |
| Primary route |
Subcutaneous injection |
| Core indications |
Chronic ITP; SAA after insufficient response to immunosuppressive therapy |
| Initial U.S. approval |
2008 |
| Pediatric ITP approval |
2018 |
| SAA approval |
2021 |
| Main competitors |
Eltrombopag, avatrombopag, fostamatinib, IVIG, corticosteroids, rituximab |
| FDA-approved biosimilars |
None identified through 2024 |
| U.S. exclusivity profile |
Biologic reference-product exclusivity has expired |
The FDA first approved Nplate in 2008 for adults with chronic ITP who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy, or who were not candidates for those treatments (FDA, 2008). The label was later expanded to pediatric patients with ITP and to adults with SAA after insufficient response to immunosuppressive therapy (FDA, 2018, 2021).
What diseases and patient segments drive romiplostim demand?
ITP remains the commercial base for Nplate. It is a chronic autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production. Treatment demand is recurring because many patients require long-term platelet support.
The principal demand segments are:
- Adults with chronic ITP requiring second-line or later-line treatment.
- Pediatric patients with persistent or chronic ITP.
- Adults with SAA who have not responded adequately to immunosuppressive therapy.
- Patients who require a parenteral TPO receptor agonist because oral treatment is unsuitable.
- Patients treated in specialist hematology centers with intensive platelet monitoring.
The SAA indication broadens the addressable market but does not transform Nplate into a mass-market hematology product. SAA is rare, and treatment decisions are concentrated among transplant and hematology specialists.
Use in chemotherapy-induced thrombocytopenia and other thrombocytopenic conditions may occur in clinical practice, but such use is not the primary basis of the FDA label. Commercial forecasts that assume broad adoption in off-label oncology applications may overstate durable Nplate demand.
How large is the romiplostim market?
The global market for thrombopoietin receptor agonists is divided among injectable and oral products. Nplate competes with eltrombopag, marketed as Promacta in the United States and Revolade in some international markets, and avatrombopag, marketed as Doptelet by Swedish Orphan Biovitrum.
Market share depends on indication, route preference, liver and renal considerations, drug interactions, formulary placement, and physician familiarity. Nplate has a strong position in patients for whom weekly injection is acceptable and in clinical settings where platelet titration and monitoring are routine.
| Market factor |
Effect on Nplate |
| Chronic ITP |
Supports recurring demand and long treatment duration |
| Weekly injection |
Differentiates Nplate but creates administration burden |
| Oral competitors |
Increase convenience-driven switching pressure |
| SAA indication |
Expands use beyond ITP |
| No approved biosimilar |
Protects price and access relative to mature small-molecule markets |
| Specialty distribution |
Supports controlled use but limits broad retail penetration |
| Platelet monitoring |
Increases clinical management requirements |
| Generic substitution |
Not applicable in the conventional small-molecule sense |
In ITP, the key commercial question is whether physicians prioritize predictable platelet response and established clinical use over oral convenience. In SAA, the decision is more dependent on treatment sequencing, transplant eligibility, immunosuppressive therapy, and institutional practice.
What is the financial trajectory of Nplate?
Amgen’s reported Nplate revenue has generally grown from the late 2010s and remained in an approximately $1 billion-plus annual range in recent years. The product has benefited from durable chronic ITP use, international expansion, pediatric adoption, and the SAA indication.
Public Amgen reporting groups Nplate as a product within the company’s portfolio but does not provide a full standalone profit-and-loss statement for romiplostim. Product sales are therefore the most reliable disclosed financial measure.
| Period |
Nplate financial direction |
Principal commercial drivers |
| 2008-2015 |
Expansion from launch base |
Adoption in chronic ITP |
| 2016-2019 |
Mature growth |
International penetration and treatment persistence |
| 2020-2021 |
Resilient demand |
Continued chronic use despite pandemic disruption |
| 2022-2023 |
Approximately $1 billion-plus annual sales |
ITP durability, pediatric use, SAA contribution |
| 2024 onward |
Mature-product trajectory |
Price, volume, geographic mix, and competition from oral agents |
Amgen’s total revenue was approximately $28 billion in 2023. Nplate’s annual sales at roughly $1.1 billion represented about 4% of company revenue, making it strategically relevant but financially smaller than products such as Prolia, Enbrel, Repatha, Otezla, or the company’s newer oncology and cardiovascular assets (Amgen, 2024).
The financial profile is attractive because manufacturing and clinical-development costs are largely sunk. Incremental revenue from additional patients can therefore carry relatively high contribution margins. The main margin risks are biologic manufacturing complexity, specialty distribution expenses, rebates, international price controls, and future competition.
When does romiplostim lose exclusivity?
Nplate’s original U.S. biologic exclusivity period has expired. Under the Biologics Price Competition and Innovation Act, an FDA-licensed reference biologic receives 12 years of reference-product exclusivity. For a product approved in 2008, that period reached its statutory endpoint around 2020, subject to regulatory calculations and pediatric exclusivity effects (FDA, 2024a).
Loss of reference-product exclusivity does not automatically produce biosimilar entry. A biosimilar applicant must still complete development, obtain FDA approval, resolve patent disputes or litigation, and establish a commercially viable manufacturing and distribution network.
The commercial exclusivity position is therefore stronger than the statutory exclusivity position. Nplate has no FDA-approved biosimilar through 2024, and no large-scale biosimilar launch has materially disrupted the product’s U.S. sales base.
What patents protect Nplate?
Romiplostim is protected by a portfolio covering the peptibody molecule, thrombopoietin receptor-binding peptides, pharmaceutical compositions, production methods, and therapeutic uses. Patent protection is distributed across U.S. and foreign patent families rather than a single patent.
The most commercially relevant patent categories are:
- Composition-of-matter claims covering romiplostim or related thrombopoietin receptor-binding constructs.
- Claims covering Fc-linked peptide architectures.
- Formulation and stability claims.
- Manufacturing and recombinant-expression processes.
- Method-of-use claims for increasing platelet counts and treating thrombocytopenia.
- Indication-specific claims involving ITP and SAA.
Exact enforceability depends on claim scope, terminal disclaimers, continuations, patent-term adjustment, and jurisdiction. Publicly available patent information should be assessed family by family because a patent’s nominal expiration date does not establish that all relevant claims remain enforceable.
What is the Orange Book and Purple Book status of romiplostim?
Nplate is a biologic, not a conventional small-molecule drug. Its regulatory reference-product and biosimilar information is therefore associated primarily with the FDA Purple Book rather than the Orange Book.
The Orange Book is relevant to approved small-molecule drugs and certain listed products. It does not provide the principal framework for Nplate’s biologic exclusivity or biosimilar competition. The Purple Book identifies the reference product and any approved biosimilar or interchangeable biological product.
Through 2024, Nplate had no FDA-approved biosimilar listed as a competing product. The absence of a biosimilar is commercially more important than the expiration of the 12-year reference-product exclusivity period because it means Amgen has not faced automatic substitution pressure comparable to generic substitution for small-molecule drugs (FDA, 2024b).
Are there romiplostim biosimilar risks?
Near-term U.S. biosimilar risk is limited but not eliminated. Romiplostim is technically more difficult to reproduce than a simple protein because its pharmacology depends on a peptide-Fc architecture, receptor-binding characteristics, aggregation control, and manufacturing consistency.
A future biosimilar developer would face several barriers:
- Demonstrating analytical similarity for a complex peptibody.
- Establishing comparable pharmacokinetics and pharmacodynamics.
- Generating sufficient clinical evidence in ITP or another sensitive population.
- Building a reliable sterile biologic manufacturing process.
- Obtaining physician and payer acceptance.
- Resolving Amgen patent claims and litigation risk.
- Funding commercial launch against a specialist product with established treatment pathways.
Biosimilar entry would probably begin with limited contracting and selected payer channels rather than immediate broad substitution. Price erosion would depend on the number of entrants, interchangeability status, hospital purchasing, and the relative attractiveness of weekly injection devices and administration services.
Which companies challenge romiplostim commercially?
How does Nplate compare with eltrombopag?
Eltrombopag is the most important commercial comparator. It is orally administered and has established use in ITP, SAA, and other hematologic settings. Oral administration gives eltrombopag a convenience advantage, but its use involves dietary and administration restrictions, drug-interaction management, and liver-related monitoring considerations.
Nplate’s advantages include:
- Long clinical experience in chronic ITP.
- Weekly dosing.
- Direct platelet-count titration.
- Established use in pediatric ITP.
- Utility when an oral agent is unsuitable.
Eltrombopag’s advantages include:
- Oral administration.
- Broader familiarity across hematology practices.
- Strong positioning in SAA.
- Avoidance of injection-site and administration concerns.
How does Nplate compare with avatrombopag?
Avatrombopag is an oral TPO receptor agonist used in ITP and other thrombocytopenic settings. It competes primarily through convenience and oral dosing. Its impact is greatest among patients and physicians who prefer oral treatment and among payers that use step therapy.
How does Nplate compare with fostamatinib?
Fostamatinib has a different mechanism, targeting spleen tyrosine kinase. It is used in chronic ITP after prior therapy and competes as an alternative for refractory patients. Its adverse-effect profile, including hypertension, diarrhea, and liver-enzyme abnormalities, affects positioning.
What non-drug treatments compete with Nplate?
Nplate also competes with corticosteroids, IVIG, rituximab, splenectomy, platelet transfusion in acute settings, and hematopoietic stem-cell transplantation in selected SAA patients. These alternatives may delay TPO receptor agonist initiation or reduce treatment duration.
What litigation and Paragraph IV risks affect romiplostim?
Paragraph IV litigation is primarily a small-molecule Hatch-Waxman mechanism and is not the standard pathway for a biologic such as Nplate. A biosimilar applicant would generally operate under the BPCIA, including the statutory patent-information exchange and potential patent litigation process.
The relevant litigation risks are therefore:
- Patent challenges to composition or formulation claims.
- Declaratory-judgment actions involving patent noninfringement or invalidity.
- Manufacturing-process disputes.
- Biosimilar patent litigation under the BPCIA.
- Contracting and market-access disputes rather than conventional generic substitution litigation.
No broad U.S. biosimilar launch or major public patent settlement had displaced Nplate through 2024. The absence of a known commercial settlement does not mean the estate is irrelevant. It means the practical barrier has remained a combination of development economics, market size, technical complexity, and patent risk.
What licensing deals and geographic rights affect romiplostim?
Amgen controls the originator franchise, while regional commercialization arrangements and local registrations can vary by market. Japan and other international markets may involve local commercial partners, distributors, or separate regulatory rights.
Geographic value differs materially:
- United States: largest strategic profit pool and most important future biosimilar market.
- Europe: mature ITP market with national reimbursement controls and growing biosimilar policy pressure.
- Japan: specialist market with local regulatory and commercial requirements.
- Emerging markets: lower price potential but room for volume expansion, subject to reimbursement and biologic manufacturing standards.
International revenue is exposed to foreign exchange, government price negotiations, tendering, and reference-pricing systems. These effects can reduce reported sales even when patient volume increases.
How strong is the romiplostim patent estate?
The estate is commercially meaningful but no longer functions as a simple launch barrier. Nplate’s strongest defenses are likely to be product complexity, manufacturing know-how, regulatory requirements, and the absence of approved competitors.
Patent strength can be assessed across four dimensions:
| Dimension |
Assessment |
| Statutory biologic exclusivity |
Expired |
| Composition patents |
Potentially important, but age and claim validity must be assessed |
| Formulation and manufacturing patents |
Relevant to design-around and biosimilar litigation |
| Regulatory and commercial barriers |
Stronger than conventional generic-drug barriers |
A biosimilar may be able to avoid a particular formulation or process claim while still requiring extensive investment to prove similarity. That makes the overall barrier broader than the patent term alone.
What generic or biosimilar launch scenarios exist for Nplate?
Scenario 1: No U.S. biosimilar through the medium term
This scenario would preserve Nplate’s existing pricing structure. Amgen would continue to manage competition through contracting, physician familiarity, supply reliability, and label breadth.
Scenario 2: One biosimilar entrant
A single entrant could produce moderate net-price erosion, especially in government and managed-care channels. The effect would likely be gradual because Nplate is administered in specialist settings and lacks automatic generic substitution.
Scenario 3: Multiple biosimilar entrants
Several entrants could create more substantial price pressure. Amgen would face contracting competition, share loss in price-sensitive systems, and potentially increased rebates. Volume could remain stable while net sales decline.
Scenario 4: Oral TPO agonist displacement
Even without biosimilar entry, oral agents could reduce Nplate use in newly diagnosed or stable ITP patients. Nplate would retain a role in patients with adherence issues, inadequate oral response, contraindications, or a preference for supervised treatment.
What is the FDA regulatory outlook for romiplostim?
Nplate is fully approved for its established indications, with the principal regulatory opportunity coming from label expansion rather than basic approval risk. Potential development areas include additional thrombocytopenic disorders, perioperative platelet support, and selected oncology or transplant applications.
Regulatory expansion faces several constraints:
- The need to distinguish approved use from off-label use.
- Thrombotic-risk management.
- Platelet-count variability.
- Competition from oral agents.
- The difficulty of proving meaningful benefit in heterogeneous thrombocytopenic populations.
- Payer resistance to broad use outside high-value indications.
The SAA approval was strategically important because it increased the product’s relevance in a rare but clinically serious disease. The indication is unlikely to produce ITP-scale volume, but it supports specialist adoption and franchise durability.
What revenue exposure does Amgen face?
Nplate is a mature, high-value specialty biologic. Its revenue exposure is meaningful at the product level but limited relative to Amgen’s total business.
The main downside channels are:
- Net-price reductions from payer contracting.
- Oral-product substitution in ITP.
- Biosimilar entry after successful development and litigation.
- Declining use in long-term responders who transition to other treatments.
- Foreign-exchange and international reimbursement pressure.
- Manufacturing interruption or supply constraints.
- Failure to expand into additional high-value indications.
The upside channels are:
- Greater penetration in pediatric ITP.
- Wider adoption in SAA.
- Increased treatment persistence.
- International diagnosis and reimbursement growth.
- Use in patients who fail oral TPO receptor agonists.
- New clinical evidence supporting earlier or broader treatment.
Key Takeaways
- Romiplostim is Amgen’s established biologic TPO receptor agonist marketed as Nplate.
- Chronic ITP remains the principal revenue base; SAA provides an important specialty indication.
- Nplate has generated approximately $1 billion-plus in annual sales in recent years, representing roughly 4% of Amgen’s total revenue.
- The 12-year U.S. reference-biologic exclusivity period has expired, but no FDA-approved romiplostim biosimilar had entered the market through 2024.
- Nplate is governed primarily by the Purple Book and BPCIA framework rather than the conventional Orange Book and Paragraph IV pathway.
- The strongest commercial defenses are manufacturing complexity, specialist use, clinical familiarity, and the absence of approved biosimilar competition.
- Eltrombopag and avatrombopag are the main commercial threats because they offer oral administration.
- Future revenue erosion is more likely to begin through oral-agent substitution or payer contracting than through immediate generic-style substitution.
- A single biosimilar could cause moderate price pressure; multiple biosimilars would create a more material threat.
- The product remains financially durable but is entering a mature phase in which lifecycle management and market access are more important than rapid volume growth.
FAQs About Romiplostim Market Dynamics
Is romiplostim still commercially protected after biologic exclusivity expired?
Yes. Statutory reference-product exclusivity has expired, but Nplate remains protected by patents, regulatory complexity, manufacturing know-how, and the lack of an approved biosimilar.
Does Nplate have an FDA-approved interchangeable biosimilar?
No FDA-approved interchangeable romiplostim biosimilar was identified through 2024.
Is romiplostim listed in the Orange Book?
Nplate is a biologic, so the Purple Book is the more relevant FDA resource for reference-product and biosimilar status. It is not evaluated like a conventional small-molecule drug under standard Orange Book substitution rules.
Which oral drug poses the greatest competitive threat to Nplate?
Eltrombopag is the most established oral comparator, while avatrombopag also creates convenience-driven switching pressure in ITP.
Can romiplostim be used for chemotherapy-induced thrombocytopenia?
Use may occur off label, but the commercial and regulatory foundation of Nplate is its approved ITP and SAA indications. Broad oncology adoption would require supportive clinical evidence and favorable reimbursement.
Why has romiplostim avoided major biosimilar erosion?
The product has a relatively specialized market, technically complex manufacturing requirements, substantial clinical-development costs, and patent and regulatory barriers. These factors can delay entry even after statutory exclusivity expires.
References
-
Amgen Inc. (2024). 2023 annual report. Amgen.
-
U.S. Food and Drug Administration. (2008). FDA approves Nplate to treat chronic immune thrombocytopenic purpura. FDA.
-
U.S. Food and Drug Administration. (2018). Nplate prescribing information. FDA.
-
U.S. Food and Drug Administration. (2021). FDA approves Nplate for adults with severe aplastic anemia. FDA.
-
U.S. Food and Drug Administration. (2024a). Biologics price competition and innovation act. FDA.
-
U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. FDA.
-
National Institutes of Health. (2024). Clinical and commercial information for romiplostim and Nplate. DailyMed.
